Financial
Latest full-year results from official filings.
FY2025 revenue $20.07bn (+19.9%); operating margin 18.0%; net income $2.90bn.
Balance sheet figures not captured from release.
- Official results release · Boston Scientific · 31 Dec 2025
Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
FY2025 revenue $20.07bn (+19.9%); operating margin 18.0%; net income $2.90bn.
Balance sheet figures not captured from release.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Aug–Sep 2026: a cyberattack forced Boston Scientific to shut plants and distribution centres globally; the company said it would likely miss its Q3 and full-year 2026 sales and earnings guidance, after two earlier guidance cuts that year.
Data breaches, cyber incidents, regulator action and assurance status.
Aug 2026: Boston Scientific disclosed to the SEC a cyberattack (detected 25 Aug) that disrupted order processing, manufacturing and shipping worldwide; it reported full restoration in Sep and said it found no evidence of compromise to its products. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
2026: FDA classed two Boston Scientific recalls as most serious: AXIOS stent delivery systems (Feb 2026; 167 serious injuries, 3 deaths reported) and unused Infinion CX spinal cord stimulator leads (Jun 2026 letter; 1,081 serious injuries, no deaths).
Contract delivery, go-lives, terminations and disputes.
Aug–Sep 2026: the cyberattack interrupted supply to hospitals; the CEO said many areas lacked adequate supply, some procedures were lost and some hospitals likely ordered from other suppliers before full restoration.